Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Biomedical technology)
83,675 results
  • Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits. [Journal Article]
  • CPClin Pharmacol 2018; 10:73-78
  • Alzoubi KH, Ismail ZB, … Abu-Baker N
  • CONCLUSIONS: Collectively, D-ribose showed a dose-dependent kinetic profile, where parameters change according to dosing levels. D-ribose clearance seems to follow first-order kinetics at low dose. Thereafter, elimination systems are saturated, and elimination continues in a fast manner. Urine recovery was partial, which could be attributed to the several metabolic pathways that pentose can undergo.
  • The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. [Journal Article]
  • PlosPLoS One 2018; 13(6):e0199446
  • Maia Diniz I, Guerra AA, … de Araújo VE
  • CONCLUSIONS: In the public health system of Brazil, disease modifying therapies currently represent almost all of the total direct costs of multiple sclerosis treatment. Around the world, new and emerging health technologies to treat of MS impose a challenge to health budgets, highlighting the need for cost-effectiveness studies comparing these technologies to those already available. Our regression model may help in this process, and calls attention to the need to access the real world performance of new therapies available in SUS, with the potential for disinvestment and/ or price reductions if needed.
New Search Next